A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats

Thrombosis Research

Volumn 117, Issue 4, 2006, Pages 429-437

  Elg, Margareta ^a   Gustafsson, David ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Dexamethasone; Disseminated intravascular coagulation; Endotoxin; Heparin; Melagatran

Indexed keywords

BLOOD CLOTTING FACTOR; DEXAMETHASONE; ENDOTOXIN; FIBRINOGEN; HEPARIN; THROMBIN INHIBITOR; TRANEXAMIC ACID; XIMELAGATRAN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; ENDOTOXEMIA; FIBRIN DEPOSITION; HEMOSTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; THROMBOCYTE AGGREGATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; THROMBIN; TREATMENT OUTCOME;

EID: 32044472809     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.03.014     Document Type: Article

References (36)

1. M. Riewald, and H. Riess Treatment options for clinically recognized disseminated intravascular coagulation Semin Thromb Hemost 24 1998 53 59
2. M.G. Vervloet, L.G. Thijs, and C.E. Hack Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock Semin Thromb Hemost 24 1998 33 44
3. B. Eisele, and M. Lamy Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure Semin Thromb Hemost 24 1998 71 80
4. K.A. Bauer, C.H. Ten, S. Barzegar, D.R. Spriggs, M.L. Sherman, and R.D. Rosenberg Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans Blood 74 1989 165 172
5. B.N. Bouma, P.A. von dem Borne, and J.C. Meijers Factor XI and protection of the fibrin clot against lysis-a role for the intrinsic pathway of coagulation in fibrinolysis Thromb Haemost 80 1998 24 27
6. C.T. Esmon The roles of protein C and thrombomodulin in the regulation of blood coagulation J Biol Chem 264 1989 4743 4746
7. S.R. Coughlin How the protease thrombin talks to cells Proc Natl Acad Sci U S A 96 1999 11023 11027
8. J. Schneiderman, and D.J. Loskutoff Plasminogen-activator inhibitors Trends Cardiovasc Med 1 1991 99 102
9. M. Saito, H. Asakura, H. Jokaji, C. Uotani, I. Kumabashiri, and E. Morishita Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy Blood Coagul Fibrinolysis 6 1995 60 64
10. D. Gustafsson, J.-E. Nyström, S. Carlsson, U. Bredberg, U.G. Eriksson, and E. Gyzander The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects Thromb Res 101 2001 171 181
11. P. Petersen New approaches to anticoagulation in atrial fibrillation Curr Cardiol Rep 6 2004 354 364
12. T. Steinmetzer, J. Hauptmann, and J. Sturzebecher Advances in the development of thrombin inhibitors Expert Opin Investig Drugs 10 2001 845 864
13. D. Gustafsson, T. Antonsson, R. Bylund, U.G. Eriksson, E. Gyzander, and I. Nilsson Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes Thromb Haemost 79 1998 110 118
14. B.I. Eriksson, G. Agnelli, A.T. Cohen, O.E. Dahl, P. Mouret, and N. Rosencher Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study Thromb Haemost 89 2003 288 296
15. C.W. Francis, S.D. Berkowitz, P.C. Comp, J.R. Lieberman, J.S. Ginsberg, and G. Paiement Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 2003 1703 1712
16. O.E. Dahl, B.I. Eriksson, G. Agnelli, A.T. Cohen, P. Mouret, and N. Rosencher Postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery: effects of timing of first dose and risk factors for thromboembolism and bleeding complications on efficacy and safety Clin Drug Invest 25 1 2005 65 77
17. S. Schulman, K. Wåhlander, T. Lundström, S.B. Clason, and H. Eriksson Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran N Engl J Med 349 2003 1713 1721
18. Executive Steering Committee on behalf of the SPORTIF III Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
19. L. Wallentin, R.G. Wilcox, W.D. Weaver, H. Emmanuelsson, A. Goodvin, and P. Nyström Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
20. M. Larsson, U. Logren, M. Ahnoff, P. Lindmark, H. Abrahamsson, and B. Svennberg Determination of melagatran, a novel direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry J Chromatogr, B, Biomed Sci Appl 766 2002 47 55
21. S.A. Gregory, J.H. Morrissey, and T.S. Edgington Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin Mol Cell Biol 9 1989 2752 2755
22. S. Gando, S. Nanzaki, S. Sasaki, and O. Kemmotsu Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation Thromb Haemost 79 1998 1111 1115
23. J. Vickers, S. Russwurm, B. Dohrn, T. Portele, P. Spangenberg, and K. Reinhart Monocyte tissue factor (CD142) and Mac-1 (CD11b) are increased in septic patients Thromb Haemost 79 1998 1219 1220
24. T. Pernerstorfer, P. Stohlawetz, U. Hollenstein, L. Dzirlo, H.G. Eichler, and S. Kapiotis Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen Arterioscler Thromb Vasc Biol 19 1999 2517 2523
25. M. Yamazaki, K. Aoshima, T. Mizutani, Y. Ontachi, M. Saito, and E. Morishita Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression Blood Coagul Fibrinolysis 10 1999 321 330
26. T. Abrahamsson, V. Nerme, M. Stromqvist, B. Akerblom, A. Legnehed, and K. Pettersson Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin Thromb Haemost 75 1996 118 126
27. L. Bajzar, J. Morser, and M. Nesheim TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex J Biol Chem 271 1996 16603 16608
28. C. Mattsson, J.A. Bjorkman, and J.C. Ulvinge Melagatran, and hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis Fibrinolysis Proteolysis 11 1997 121 128
29. U.G. Eriksson, U. Bredberg, K.-J. Hoffmann, A. Thuresson, M. Gabrielsson, and H. Ericsson Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans Drug Metab Dispos 31 2003 294 305
30. M.F. Levett, and M.E. Bader Effect of cortisone and ACTH on fluid and electrolyte distribution in man Am J Med 11 1953 715 723
31. J.M. Connell, J.A. Whitworth, D.L. Davies, A.F. Lever, A.M. Richards, and R. Fraser Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man J Hypertens 5 1987 425 433
32. G.J. Wiegers, and J.M. Reul Induction of cytokine receptors by glucocorticoids: functional and pathological significance Trends Pharmacol Sci 19 1998 317 321
33. R. Bertini, M. Bianchi, and P. Ghezzi Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor J Exp Med 167 1988 1708 1712
34. R.C. Bone, C.J. Fisher Jr., T.P. Clemmer, G.J. Slotman, C.A. Metz, and R.A. Balk A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock N Engl J Med 317 1987 653 658
35. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group N Engl J Med 317 1987 659 665
36. P.C. Minneci, K.J. Deans, S.M. Banks, P.Q. Eichacker, and C. Natanson Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose Ann Intern Med 141 2004 47 56